Healiva SA
- Industry
- Biotechnology
- Founded Year
- 2020
- Headquarters
- Lugano, Switzerland
- Employee Count
- 0
Key People
-
Dr. Priyanka Dutta-Passecker - Co-founder and CEO
Email: contact@healiva.com
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team, led by Dr. Priyanka Dutta-Passecker, brings over a decade of experience in biotech and precision medicine.
Dr. Dutta-Passecker's background in biotech and precision medicine, combined with the team's expertise, provides a solid foundation for the company's initiatives.
- Clinical Need
-
Aspect: Very Strong
Summary: Healiva addresses a significant unmet need in chronic wound care, offering personalized therapies for non-healing wounds.
With 60% of chronic wounds remaining unhealed and a growing patient population, Healiva's solutions target a pressing clinical need.
- Competition
-
Aspect: Somewhat crowded
Summary: The wound care market has several players, but Healiva's personalized approach differentiates it.
The market includes various wound care solutions; however, Healiva's integration of enzyme technology, cell therapies, and medical devices offers a distinctive value proposition.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing personalized cell therapies involves moderate technical challenges, but Healiva's acquisitions bolster its capabilities.
The acquisition of manufacturing assets from B. Braun and Smith+Nephew enhances Healiva's technical capacity to develop and produce advanced therapies.
- Patent
-
Aspect: Strong
Summary: Healiva has acquired critical assets and technologies, strengthening its intellectual property portfolio.
Acquisitions from established companies like Smith+Nephew provide Healiva with proprietary technologies and potential patent protections.
- Financing
-
Aspect: Medium
Summary: Healiva has secured seed funding and is actively seeking additional investments to support its growth.
While initial funding has been obtained, further capital is essential to advance clinical development and commercialization efforts.
- Regulatory
-
Aspect: Pivotal Trial
Summary: Healiva is progressing through pivotal trials, with plans for market launch pending regulatory approvals.
The company's acquisition of assets with prior market approval in Switzerland positions it favorably, but navigating regulatory pathways remains a key challenge.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 5.1
- Segment CAGR
- 5.4%
- Market Segment
- Wound Care Management
- Market Sub Segment
- Chronic Wound Therapies
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.26 |
| 2 | 0.76 |
| 3 | 1.78 |
| 4 | 3.57 |
| 5 | 5.10 |
Key Takeaway
Healiva's innovative approach to chronic wound care positions it well in a growing market, but securing additional funding and navigating regulatory pathways are crucial for success.